Starling Oncology Q3 2026 Results: Net Loss of $15.7M, Loss Narrows
Starling Oncology, Inc. reported a significant revenue increase to $478.5 million for the nine months ended September 30, 2026, driven primarily by growth in its Specialty Pharmacy segment. Despite this growth, the company remains unprofitable with a net loss of $28.0 million for the period and a total stockholders' deficit of $37.4 million.
- Key figure
- Net loss $15.7M